Bu çalışmanın amacı, allerjik rinitin eşlik ettiği astımlı çocuklarda, rinit tedavisinde kullanılan tekdoz setirizinin, adenozin monofostat (AMP) ile gelişen bronşial hiperreaktivite (BHR) üzerine etkisinin incelenmesidir.Çalışmaya bölümümüzde takip edilen, astımla beraber mevsimsel allerjik riniti olan 7-16 yaş arası 26 hasta alınmıştır. Bu çalışma randomize çift kör ve plasebo kontrollü ve çapraz bir çalışma olarak planlanmıştır. Hastalar kliniğimizde 3 kez görülmüşlerdir. İlk vizitte hastalara Adenozin monofostatla (AMP) ile bronş provokasyon testi yapılıp, PC20 değeri £ 200 mg/ml olanlar 3 gün içerisinde 2. vizite çağrılmışlardır. 2. vizitte solunum fonksiyon testini takiben hastalara randomize olarak ya 10 mg setirizin tablet ya da plasebo verilmiş ve 120 dakika sonra AMP ile bronş provakasyon testine bakılmıştır. 2. vizitten en az 2 gün sonra 3. vizit yapılmış ve benzer prosedürler uygulanmıştır. Çalışmayı tamamlayan 18 hastada Setirizin alan grupta 2. saatte ölçülen PC20AMP değerinin geometrik ortalaması plasebo grubuyla karşılaştırıldığında daha yüksek bulunmuştur (sırasıyla 55.5 ± 5.90 mg/ml ve 17.89 ± 6.38 mg/ml, p<0.05 ). Başka bir deyişle setirizin ortalama geometrik PC20AMP’ yi plaseboya göre 1.58 kat, bazal değere göre 1.65 ikiye katlayan dilusyonda düzeltmiştir. Bu çalışma, astım ve alerjik rinitli çocuklarda setirizinin AMP ile olan bronşprovakasyonunu düzelterek önemli bir antiinflamatuvar etkinliğinin olduğunu göstermiştir. Bu nedenle setirizin sadece alerjik rinitin semptomatik tedavisinde değil aynı zamanda astımı da olan çocuklarda da ek tedavi olarak kullanılabilir. Setirizinin alerjik hastalık spektrumundaki kullanımı için uzun dönem çalışmalar, serum eozinofili, balgam eozinofili, soluk havasında nitrik oksit düzeyi gibi diğer inflamatuvar parametreler üzerine olan etkinliğinin araştırılması gerekmektedir.
We investigated the effect of single dose cetrizine which is used in rinitis, on brochial hyperreactivity
due to adenosine monophosphat ( AMP ) in children with asthma and associated allergic rhinitis.
Twentysix children aged 7 to 16 years, with a history of both seasonal allergic rhinitis and asthma
were enrolled in this study which was conducted as a randomized, double-blind, placebocontrolled and cross-over fashion. The patients were seen 3 times in our clinic. At the first visit they
were given bronchial provocative test with AMP. The ones having a PC value of £ 200mg/ml to 20
AMP were called for the second vizit within 3 days. In this visit , he/she was given randomly either
cetrizine 10 mg tablet or placebo after a baseline spirometry. Bronchial challenge with AMP was
started at the 120. minute. The same procedure was repeated at vizit 3, at least 2 days after the vizit
2.
All of the eighteen patients who were able to complete the study protocol demonstrated
significantly better geometric mean of AMP PC values with cetrizine (55.5 ± 5.90 mg/ml) com- 20
pared to those with placebo (17.89 ± 6.38 mg/ml) (P<0.05). In other words, cetrizine improved
geometric mean of AMP PC values 1.58 times as compared to placebo and 1.65 times when 20
compared to basal levels.
In conclusion, this study demonstrates that cetrizine has an important anti-inflammatory effect by
improving AMP PC in children with both asthma and associated allergic rhinitis. Therefore 20
cetrizine may be considered not only for symptomatic treatment of allergic rhinitis but also as an
add-on treatment in children who have asthma allergic rhinitis. Further studies are needed to
determine the long-term effects of cetrizine on, allergic diseases as well as on other inflammatory
markers as exhaled nitric oxide, serum and sputum eosinophilia
Other ID | JA57DH38RD |
---|---|
Journal Section | Research Article |
Authors | |
Publication Date | August 1, 2008 |
Submission Date | August 1, 2008 |
Published in Issue | Year 2008 Volume: 2 Issue: 1 |
The publication language of Turkish Journal of Pediatric Disease is English.
Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.
The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.